Acceleron Pharma To Present Luspatercept Clinical Trials At The 20th Congress Of The European Hematology Association

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced that data from two ongoing phase 2 clinical trials of luspatercept in patients with beta-thalassemia and myelodysplastic syndromes (MDS) will be given as oral presentations at the 20th Congress of the European Hematology Association in Vienna, Austria.

Help employers find you! Check out all the jobs and post your resume.

Back to news